Phase 2 Pancreatic Cancer Trial, Recruiting NCT07114315 Sponsor: Akeso Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT07114315
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to sign a written consent form agreeing to take part.
  • People who are expected to live for at least 3 months.
  • People who have a good general level of physical functioning, rated 0 or 1 on a standard oncology scale (meaning fully active or able to do light activity — confirm with trial site).
  • People who have been diagnosed with advanced or spreading pancreatic cancer (a specific type called pancreatic ductal adenocarcinoma), confirmed through a tissue or cell sample, and whose cancer has continued to grow after receiving 1 or 2 previous cancer treatments.
  • People who have at least one tumour that can be measured on a scan, using standard criteria called RECIST v1.1.
  • People whose liver, kidneys, and other organs are functioning well enough to meet the trial's requirements.
  • People of reproductive potential who agree to use an effective method of contraception during the trial and for 90 days after the last dose of the study treatment.
  • People who are able to follow all the requirements and procedures involved in the trial.

Who may not be able to join:

  • People who have had another type of cancer (other than pancreatic ductal adenocarcinoma) within the past 5 years.
  • People who have cancer that has spread to the brain, spinal cord, or the lining around the brain and spinal cord.
  • People who have fluid build-up around the lungs, heart, or abdomen that is causing symptoms or needing to be drained repeatedly.
  • People who have previously been treated with a type of drug that blocks TGF-β or with anti-angiogenic drugs (medicines that target blood vessel growth in tumours).
  • People who have a history of non-infectious lung inflammation that required treatment with steroid medication.
  • People with a history of serious bleeding problems or issues with blood clotting.
  • People with a history of heart muscle inflammation, disease of the heart muscle, or serious irregular heart rhythms.
  • People who are pregnant or currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 18116403289

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Akeso
Registry
ClinicalTrials.gov
Start date
19 September 2025
Est. completion
1 August 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of subjects with adverse events (AEs); Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov